Global Core Needle Biopsy Devices Market Size By Type (Full-automatic Core Needle Biopsy Device, Semi-automatic Core Needle Biopsy Device), By Application (Hospitals, Clinics), By Region, And Segment...

lobal Core Needle Biopsy Devices Market Report Description

The Global Core Needle Biopsy Devices Market was valued at USD 745 million in 2023 and is projected to reach USD 1.31 billion by 2031, growing at a CAGR of 7.3% during the forecast period from 2023 to 2031. This growth is driven by the increasing prevalence of cancer, the growing demand for minimally invasive diagnostic procedures, and the technological advancements in biopsy techniques. Core needle biopsy (CNB) devices offer improved accuracy, faster recovery, and reduced risk compared to traditional surgical biopsy methods, making them increasingly preferred across healthcare settings globally.

Drivers:

1. Rising Incidence of Cancer:

The increasing global burden of cancer, particularly breast, prostate, and lung cancers, is fueling the demand for accurate and early diagnostic tools. Core needle biopsy devices are essential in cancer diagnosis and staging.

2. Shift Toward Minimally Invasive Procedures:

Minimally invasive diagnostic approaches, such as CNB, are gaining popularity due to lower complication rates, reduced recovery times, and cost-effectiveness compared to open surgical biopsies.

3. Advancements in Biopsy Technologies:

Innovations such as vacuum-assisted biopsy systems, image-guided CNB devices, and integration with AI-enhanced imaging tools are enhancing procedural accuracy and patient outcomes.

Restraints:

1. Risk of Complications:

Although minimally invasive, CNB still carries risks such as bleeding, infection, or inconclusive results, which may deter some physicians from its routine use.

2. Limited Access in Low-Income Regions:

In developing economies, limited access to advanced diagnostic tools and a shortage of trained radiologists and pathologists can hamper market penetration.

Opportunity:

1. Emerging Markets and Healthcare Infrastructure Expansion:

Countries in Asia-Pacific, Latin America, and the Middle East are witnessing substantial growth in healthcare infrastructure, presenting untapped opportunities for CNB device manufacturers.

2. Growing Adoption in Ambulatory Care Centers:

The shift toward outpatient care models is creating demand for compact, cost-effective biopsy devices suitable for ambulatory and point-of-care settings.

Market by System Type Insights:

By system type, the automated core needle biopsy devices segment accounted for the largest share in 2023 due to ease of use, consistent sample quality, and integration with imaging technologies. However, semi-automated devices are gaining traction in low-resource settings due to their affordability and reliability in less complex procedures.

Market by End-use Insights:

Hospitals dominated the market in 2023, owing to the availability of advanced diagnostic imaging and trained professionals. Diagnostic centers and ambulatory surgical centers are projected to witness robust growth, driven by decentralization of healthcare and increasing demand for early detection services outside of traditional hospital settings.

Market by Regional Insights:

North America held the largest market share in 2023, led by the U.S., driven by high healthcare expenditure, strong cancer screening programs, and early adoption of advanced diagnostic devices. Asia-Pacific is expected to register the fastest growth due to improving healthcare systems, government initiatives for cancer awareness, and a rising aging population.

Competitive Scenario:

Leading players in the Global Core Needle Biopsy Devices Market include:

Becton, Dickinson and Company

Hologic, Inc.

Cook Medical

Argon Medical Devices

Cardinal Health

Olympus Corporation

INRAD Inc.

Medtronic plc

These companies are actively investing in R&D, strategic collaborations, and regional expansion to capture a larger share in emerging markets and cater to evolving clinical needs.

Scope of Work – Global Core Needle Biopsy Devices Market

Report Metric Details

Market Size (2023) USD 745 million

Projected Market Size (2031) USD 1.31 billion

CAGR (2023–2031) 7.3%

Market Segments By System Type, By End-Use, By Region

Growth Drivers Rising cancer prevalence, shift to minimally invasive diagnostics, tech innovations

Opportunities Expansion in emerging markets, adoption in ambulatory care centers

Key Market Developments:

March 2023: Hologic Inc. introduced a next-generation vacuum-assisted core biopsy system with integrated imaging compatibility for breast cancer screening.

August 2024: BD launched a portfolio of semi-automated CNB devices aimed at increasing accessibility in low- and middle-income countries.

January 2025: Cook Medical partnered with leading diagnostic chains in India and Brazil to distribute cost-effective CNB kits with training support.

FAQs:

1) What is the current market size of the Global Core Needle Biopsy Devices Market?

The market was valued at USD 745 million in 2023.

2) What is the major growth driver of the Global Core Needle Biopsy Devices Market?

The key driver is the increasing global incidence of cancer and rising demand for minimally invasive diagnostic solutions.

3) Which is the largest region during the forecast period in the Global Core Needle Biopsy Devices Market?

North America is projected to remain the largest regional market.

4) Which segment accounted for the largest market share in Global Core Needle Biopsy Devices Market?

The automated core needle biopsy devices segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Core Needle Biopsy Devices Market?

Key players include Becton, Dickinson and Company, Hologic, Cook Medical, Argon Medical Devices, and Cardinal Health.

Let me know if you'd like a downloadable version of this in DOCX or PDF format.